公司資料
Teva Pharmaceutical Industries 股價、新聞與催化劑
- 股票代碼:
- TEVA
- 交易所:
- NYSE
- 產業:
- Biopharma
- 所在地:
- Israel and listed in the U
股票表現
36.46 USD (-0.84%)
收盤價
最後更新: 2026年8月17日
38.5B USD
市值
股價為何變動
As of Aug 17, 2026, TEVA closed down 0.84% at $36.46. No new same-company headline was identified in the current news window.
公司概覽
Global Generics and Innovative Medicines Company
Teva Pharmaceutical Industries is a global pharmaceutical company combining a large generics base with a growing innovative medicines portfolio. Its current strategy, Pivot to Growth, is shifting the company toward higher-value innovative brands, biosimilars, and late-stage pipeline assets while modernizing operations.
Innovative Brand Growth
Teva's key innovative brands are AUSTEDO, AJOVY, and UZEDY. Together they generated more than $1 billion in second-quarter 2026 revenue and grew 43% year over year in local currency. This portfolio is transforming Teva's revenue mix and supports the company's raised 2026 outlook for all three brands.
Generics and Biosimilars Powerhouse
Generics revenue declined in the quarter, largely due to lower U.S. lenalidomide revenue as competition increased. At the same time, Teva is building biosimilars as a growth area, including the European launch of AHZANTIVE and a collaboration with Polpharma Biologics for a proposed Ocrevus biosimilar.
Late-Stage Neuroscience and Immunology Pipeline
Teva is expanding its innovative pipeline through assets such as ecopipam for Tourette syndrome, olanzapine LAI for schizophrenia, TEV-'408 for vitiligo, and duvakitug with Sanofi for inflammatory bowel disease and additional immune-mediated indications. This gives the company a more diversified growth profile beyond mature generics.
未來催化劑
- Potential U.S. launch of olanzapine LAI in the fourth quarter of 2026, subject to approval.
- FDA review of ecopipam after NDA submission in June 2026.
- Phase 2 initiation for TEV-'408 in vitiligo expected in the fourth quarter of 2026.
- Additional duvakitug studies in hidradenitis suppurativa and fibrostenotic Crohn's disease.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。